

Buprenorphine service development for PWUD under GF/DDC Target = 5 MMT sites / 2021-22

Evaluation Questions:

Clinical? Bup/nalox vs Methadone ปกติ

- age 18+ , DSM V, urine +ve
- inform consent – open-label free selection 2 choices
- Induction – stabilization – maintenance – 6-12 months
- Safety, Relapse, QoL, Employment, Crime

Service & Costs?

- visits, hospitalization, satisfaction, retention
- provider costs, patient costs, switching costs

Special groups?

- HIV +ve, HCV +ve, mountainous areas, youths

Buprenorphine service development for PWUD under GF/DDC Target = 5 MMT sites / 2021-22

Evaluation Questions: ความพยายาม ในปี 2016

THAI SUBOXONE OUTCOME STUDY

NO CIRCULATION WITHOUT PERMISSION

Effectiveness of Suboxone Film Maintenance Treatment in Thailand A prospective, observational study

CLINICAL STUDY PROTOCOL V1.0

Study Identifiers

UoA:	THAI/SUBOXONE/2016
IRB Number:	XXX
Funder's reference	XXX

Sponsor

Name:	University of Adelaide
Address:	Frome Road Adelaide South Australia, Australia. 5000
Telephone:	+61 8 8313 5208

Co-Chief Investigator

Name:	Professor Robert Ali MBBS FACHAM FAFPHM
Address:	Discipline of Pharmacology School of Medicine University of Adelaide South Australia
Telephone:	+61 8 83138055
Email:	robert.ali@adelaide.edu.au

Co-Chief Investigator

Name:	Professor John Marsden PhD, AFBPsS, C.Psychol., PgDip CBT,
Address:	Addictions Department, Institute of Psychiatry, Psychology & Neuroscience hello King's College London, United Kingdom
Telephone:	+44 20 7848 0830
Email:	john.marsden@kcl.ac.uk

Buprenorphine service development for PWUD under GF/DDC Target = 5 MMT sites / 2021-22

Effectiveness Evaluation Study:

Population – Opium/Heroin dependence patients

Intervention – Medication-Assisted Treatment with **Bup./nalox.**

Control – **existing** Medication-Assisted Treatment with **Methadone**

Outcomes –Retention (Compliance, Clinical, Crimes, Costs)

Evaluation under routine setting,

no need for randomized control trial (RCT)

Buprenorphine service development for PWUD under GF/DDC Target = 5 MMT sites / 2021-22

Effectiveness Evaluation Study:

> **Prospective, observational, open-label F-U study**

Setting- 5 MMT clinics

Primary objective – Retention at 6 months

Secondary objectives – Clinical, Compliance, Crimes, Costs

Recruitment- New cases or MMT drop-out – voluntary

Sample size- 200 Bup./Nalox. 200 MMT in same site